Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test‐Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients
The Journal of Clinical Pharmacology · 2023-09 · 63 (9) · 1026-1035
DOI: 10.1002/jcph.2257 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 09.06.2023. Verfasst von Tyler C Dunlap und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Busulfan, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Busulfan is an alkylating agent used as part of conditioning chemotherapy regimens prior to allogeneic hematopoietic cell transplant (allo‐HCT). Pharmacokinetic (PK)‐guided test‐dose strategies have been shown to improve the number of patients achieving busulfan exposure goals and improve clinical outcomes. However, current practices require extensive PK sampling. In this study, PK data were retrospectively collected from busulfan drug monitoring records from adult allo‐HCT recipients who received once‐daily intravenous busulfan at the University of North Carolina Medical Center (UNCMC). A population pharmacokinetic (popPK) model was developed to identify sources of interindividual variability and evaluate alternative PK sampling strategies. A 2‐compartment model, with covariate effects of actual body weight and sex, best described the data. The typical value of clearance for an 83 kg male was estimated to be 11.21 L/h. Fifty‐nine percent of allo‐HCT recipients were estimated to have met the UNCMC institutional myeloablative conditioning (MAC) exposure goal based on model post hoc estimates of clearance using all PK samples obtained following MAC dosing. Fifty‐seven percent of patients were estimated to have met this goal based on post hoc estimates using a single PK sample. Our results indicate once‐daily, intravenous busulfan PK in adult allo‐HCT recipients receiving MAC dosing can be reasonably described by a popPK model, and the use of a sparse PK sampling strategy may be feasible for determining target exposure attainment following MAC dosing. Use of a popPK model and sparse PK sampling strategy to carry out busulfan test‐dose procedures could reduce health care costs and inconvenience to patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
- Bone Marrow Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC, USA.
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
- Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
- Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
ORCID-Profile: Tyler C Dunlap, Daniel L Weiner, Ryan M Kemper, J Ryan Shaw, Paul M Armistead, Jonathan R Ptachcinski, Daniel J Crona
Förderung
- NIGMS NIH HHS
Zitieren
APA
Dunlap, T. C., Weiner, D. L., Kemper, R. M., Kardouh, M., DeVane, S. C., Symonds, A., Shaw, J. R., Armistead, P. M., Ptachcinski, J. R., & Crona, D. J. (2023). Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test‐Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients. The Journal of Clinical Pharmacology, 63(9), 1026-1035. https://doi.org/10.1002/jcph.2257
Vancouver
Dunlap TC, Weiner DL, Kemper RM, Kardouh M, DeVane SC, Symonds A, et al. Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test‐Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients. The Journal of Clinical Pharmacology. 2023;63(9):1026-1035. doi:10.1002/jcph.2257
BibTeX
@article{Dunlap2023,
author = {Dunlap, Tyler C and Weiner, Daniel L and Kemper, Ryan M and Kardouh, Miramar and DeVane, Susanna C and Symonds, Allison and Shaw, J Ryan and Armistead, Paul M and Ptachcinski, Jonathan R and Crona, Daniel J},
title = {Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test‐Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients},
journal = {The Journal of Clinical Pharmacology},
year = {2023},
volume = {63},
number = {9},
pages = {1026--1035},
doi = {10.1002/jcph.2257}
}
EUVIMED